阿尔茨海默病血液标志物临床转化的挑战和展望  

Clinical translation of blood biomarkers for Alzheimer's disease:Challenges and Perspectives

作　　者：王俊 黄珊 王延江 Jun WANG;Shan HUANG;Yanjiang WANG(Department of Neurology and Centre for Clinical Neuroscience,Daping Hospital,Third Military Medical University,Chongqing,China)

机构地区：[1]陆军军医大学大坪医院(陆军特色医学中心),神经内科,重庆400042

出　　处：《阿尔茨海默病及相关病杂志》2024年第4期287-292,共6页Chinese Journal of Alzheimer's Disease and Related Disorders

基　　金：国家重点研发计划(项目编号:2023YFC3605400)。

摘　　要：阿尔茨海默病(Alzheimer's disease,AD)的早期治疗取得突破性进展,早期、准确诊断AD迫在眉睫。血液生物标志物是早期诊断的理想工具,在AD临床诊疗方面应用前景广阔,近年取得较大研究进展,但在转化应用中面临系列挑战。对AD血液生物标志物临床转化中的挑战进行分析,并提出应对策略,旨在推动AD血液生物标志物走向临床实践。The early treatment of Alzheimer's disease(AD)has made a breakthrough,making it urgent for early and accurate diagnosis of AD.Blood biomarkers are ideal tools for early diagnosis and have promising application prospects.Great research progresses have been made in recent years,but a series of challenges still exist in the translational application of blood biomarkers.Here,we dissected these challenges and proposed strategies to facilitate AD blood biomarkers to clinical practice.

关 键 词：阿尔茨海默病 血液生物标志物 诊断 转化研究 临床实践 

分 类 号：R741.05[医药卫生—神经病学与精神病学]